|
|
|
|
|
|||||||
|
Session 72
Poster Session
Treatment Interruption 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 528-M. | SSITT: A Prospective Trial of Treatment Interruptions in HIV Infection B. Hirschel*1, C. Fagard1, A. Oxenius2, H. Gunthard3, and F. Garcia4 for the Swiss HIV Cohort Study 1Geneva, Switzerland; 2Oxford, UK; 3Zürich, Switzerland; and 4Barcelona, Spain
| ||
| 529-M. | Structured Treatment Interruptions (STI) in Patients Receiving HAART since Primary HIV-1 Infection (PHI): Spontaneous Control of Viremia in about One Third of Cases after the First 3 Cycles Off Therapy J. Miró*1, M. Plana, G. M. Ortiz2, M. J. Maleno1, M. Arnedo1, A. del Rio1, X. Claramonte1, A. Garcia1, E. Lazzari1, J. Joseph1, T. Pumarola1, D. F. Nixon2, T. Gallart1, and J. M. Gatell1 1Univ. of Barcelona, Spain and 2Univ. of California, San Francisco
| ||
| 530-M. | Structured Treatment Interruptions (STI) in Acute Seroconverters: Interim Results of the Multicenter Prospective PRIMSTOP Pilot Trial (ANRS 100) B. Hoen*1, M. Burgard2, I. Fournier3, C. Lacabaratz4, F. Raffi5, M. Lafaurie6, J. M. Livrozet7, C. Rouzioux2, A. Venet4, and J. P. Aboulker3 for the Primstop Study Team 1Univ. Hosp., Besançon; 2Hosp. Necker, Paris; 3INSERM SC10, Paris; 4Univ. of Paris-Sud, Le Kremlin-Bicetre; 5Univ. Hosp., Nantes; 6Hosp. Saint-Louis, Paris; and 7 Univ. Hosp., Lyon, France
| ||
| 531-M. | Long-Term Multicompartment Evolutionary Study of HIV-env in a Chronically HIV-Infected Patient before and during HAART Followed by 5 Structured Treatment Interruptions (STI) B. Joos*1, M. Fischer1, A. Trkola1, J. Böni3, H. Kuster1, A. Oxenius4, J. K. Wong5, R. Phillips4, B. Hirschel2, R. Weber1, and H. Gunthard1 Univ. Hosp., 1Zürich and 2Geneva; and 3NZR Univ., Zürich, Switzerland; 4Oxford Univ., UK; and 5Univ. of California, San Diego
| ||
| 532-M. | Drug-Resistant HIV-1 Variants Selected in Children with Intermittent Low-Level Plasma HIV-1 RNA (Blips) during HAART N. H. Tobin*1, Y. Wang1, A. J. Melvin1, S. DeVange1, J. McKernan1, G. M. Ellis1, K. M. Mohan1, G. Pepper1, L. Heath1, W. E. Naugler1, I. A. Beck1, P. Lewis2, G. H. Learn1, J. Mullins1, and L. M. Frenkel1 1Univ. Washington, Seattle and 2Oregon Hlth. Sci. Univ., Portland
| ||
| 533-M. | Maintenance Therapy with HU-ddI after Complete Viral Suppression on HAART: Results at 48 Weeks P. Barreiro*, N. Camino, C. de Mendoza, V. Soriano, F. Blanco, E. Valencia, and J. Gonzalez-Lahoz Hosp. Carlos III, Madrid, Spain
| ||
| 534-M. | Effect of Associating an Immunosuppressive Therapy (Mycophenolate Mofetil: MMF)+HAART during STI and Holding the MMF Drug after Definitive Interruption of HAART on Viral Replication F. García1, M. Plana*1, M. Brunet1 , M. Arnedo1, J. Alcami2, C. Lopez-Galindez2, K. Tenner-Racz3, C. Gil1, E. Vidal1, G. Mestre1, J. Martorell1, A. Cruceta1, J. Miró1, T. Pumarola1, T. Gallart1, P. Racz3, and J. M. Gatell1 1Univ. of Barcelona, Spain; 2Inst. Carlos III, Madrid, Spain; and 3Bernhard-Nocht-Inst., Hamburg, Germany
| ||
| 535-M. | Effect of Associating a Cytostatic Drug+HAART and Holding the Cytostatic Drug after STI and a Definitive Interruption of HAART on HIV-1-Specific Immune Responses M. Plana*1, L. Lopalco2, F. García1, G. M. Ortiz3, M. J. Maleno1, A. García1, J. Arostegui1, J. Miró1, D. F. Nixon3, C. Gil1, A. Cruceta1, M. Arnedo1, T. Pumarola1, J. Alcami4, F. Lori5, T. Gallart1, and J. M. Gatell1 1Univ. of Barcelona, Spain; 2San Raffaele Sci. Inst., Milan, Italy; 3Univ. of California, San Francisco; 4Inst. Carlos III, Madrid, Spain; and 5Res. Inst. for Genetic and Human Therapy, Georgetown Univ., Washington, DC
| ||
| 536-M. | Viral Rebound after Suppression with HAART: Experience from 237 People with Viral Load < 50 copies/mL Followed for up to 4.4 Years F. Lampe, M. A. Johnson, C. Loveday, M. Youle, D. Ransom, C. Sabin, M. Tyrer, and A. N. Phillips* Royal Free Hosp. Clin., Univ, Coll. of London, UK
| ||
| 537-M. | Sequential Broadening of HIV-1-Specific CTL Responses during Supervised Treatment Interruption in Treated Acute Infection X. Yu*1, M. M. Addo1, C. Fitzpatrick , P. Lee, D. Strick, P. Goulder, E. Rosenberg2, B. Walker3, and M. Altfeld1 1Partners AIDS Res. Ctr.; 2Massachussetts Gen. Hosp.; and 3Harvard Med. Sch., Boston, MA
| ||
| 538-M. | HIV-Specific CTL Responses do not Prevent Early Viral Rebound and Immunological Deterioration after STI in Chronic HIV Infection J. van Lunzen*1, N. Frahm1, J. Schmitz3, M. Kuroda3, B. Walker2, H. J. Stellbrink1, and M. Altfeld2 1Univ. Hosp. Eppendorf, Hamburg, Germany; 2Partners AIDS Res. Ctr., Massachusetts General Hosp., Boston; and 3Beth Israel Deaconess Med. Ctr., Boston, MA
| ||
| 539-M. | Effector/Memory CD8 T-Cell Dynamics in HIV-Infected Patients during HAART Discontinuation and Resumption G. D'Offizi*, M. Amicosante, C. Montesano, C. Gioia, S. Topino, C. Agrati, L. Pucillo, P. Narciso, and F. Poccia Natl. Inst. for Infectious Diseases, L. Spallanzani, Rome, Italy
|
